HALO240719C25000
- 27.18
- 0.000.00%
Halozyme Therapeutics Newsroom
Form 144 | Halozyme Therapeutics(HALO.US) Officer Proposes to Sell 520.4K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 28, $Halozyme Therapeutics(HALO.US)$ Officer NICOLE LABROSSE intends to sell 10,000 shares of its common stock on Jun 28, with a total market value of approximately $520.4K
Halozyme Therapeutics(HALO.US) Officer Sells US$1.56 Million in Common Stock
$Halozyme Therapeutics(HALO.US)$ Officer LaBrosse Nicole sold 30,000 shares of common stock on Jun 26, 27, 28, 2024 at an average price of $51.931 for a total value of $1.56 million.Source: Announceme
Form 144 | Halozyme Therapeutics(HALO.US) Officer Proposes to Sell 519.34K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 27, $Halozyme Therapeutics(HALO.US)$ Officer NICOLE LABROSSE intends to sell 10,000 shares of its common stock on Jun 27, with a total market value of approximately $519.34
Form 144 | Halozyme Therapeutics(HALO.US) Officer Proposes to Sell 518.2K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 26, $Halozyme Therapeutics(HALO.US)$ Officer NICOLE LABROSSE intends to sell 10,000 shares of its common stock on Jun 26, with a total market value of approximately $518.2K
Halozyme Therapeutics Is Maintained at Buy by Benchmark
Halozyme Therapeutics Is Maintained at Buy by Benchmark
Benchmark Co. Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Raises Target Price to $60
Benchmark Co. analyst Robert Wasserman maintains $Halozyme Therapeutics(HALO.US)$ with a buy rating, and adjusts the target price from $50 to $60.According to TipRanks data, the analyst has a success
Express News | Halozyme Therapeutics Inc : Benchmark Raises Target Price to $60 From $50
Roche's OCREVUS SC Administration Approved by European Commission
Express News | Halozyme Announces Roche's Ocrevus® Sc With Enhanze® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis
Halozyme Therapeutics (NASDAQ:HALO) Shareholder Returns Have Been Stellar, Earning 193% in 5 Years
Decoding 12 Analyst Evaluations For Halozyme Therapeutics
Throughout the last three months, 12 analysts have evaluated Halozyme Therapeutics (NASDAQ:HALO), offering a diverse set of opinions from bullish to bearish.The following table provides a quick overvi
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $65
H.C. Wainwright analyst Mitchell Kapoor maintains $Halozyme Therapeutics(HALO.US)$ with a buy rating, and maintains the target price at $65.According to TipRanks data, the analyst has a success rate o
Express News | HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $65 Price Target
Halozyme Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/24/2024 26.09% HC Wainwright & Co. $65 → $65 Reiterates Buy → Buy 06/07/2024 -1.07% Piper Sandler $48 →
Express News | Halozyme Announces argenx Receives FDA Approval for Vyvgart® Hytrulo Co-Formulated With Enhanze® for Chronic Inflammatory Demyelinating Polyneuropathy
Bristol Myers Opdivo Injectable Accepted for EU Review
Halozyme Therapeutics(HALO.US) Officer Sells US$494.26K in Common Stock
$Halozyme Therapeutics(HALO.US)$ Officer LaBarre Michael J. sold 10,000 shares of common stock on Jun 18, 2024 at an average price of $49.426 for a total value of $494.26K.Source: Announcement What is
TD Cowen Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $59
TD Cowen analyst Brendan Smith maintains $Halozyme Therapeutics(HALO.US)$ with a buy rating, and maintains the target price at $59.According to TipRanks data, the analyst has a success rate of 27.3% a
Form 144 | Halozyme Therapeutics(HALO.US) Officer Proposes to Sell 494.26K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 18, $Halozyme Therapeutics(HALO.US)$ Officer MICHAEL LABARRE intends to sell 10,000 shares of its common stock on Jun 18, with a total market value of approximately $494.26
Don't Ignore The Insider Selling In Halozyme Therapeutics
We wouldn't blame Halozyme Therapeutics, Inc. (NASDAQ:HALO) shareholders if they were a little worried about the fact that Matthew Posard, the Independent Director recently netted about US$1.0m sellin